What disease does entrectinib treat?

Entrectinib is a targeted therapy drug used to treat certain types of cancer. It is designed to target tumors carrying NTRK gene fusion mutations and tumor types such as ROS1-positive non-small cell lung cancer.

NTRKgene fusions are a rare but important form of cancer mutation that cause the nerve growth factor receptor (NTRK) gene to fuse with other genes, producing an abnormal protein. This abnormal protein promotes tumor growth and spread in some tumors. By specifically inhibiting the activity of this abnormal protein, entrectinib blocks the growth and spread of cancer cells and effectively inhibits tumor progression.

In addition, entrectinib is also used to treatROS1positive non-small cell lung cancer. ROS1Gene fusion is another cancer mutation that causes the ROS1 gene to fuse with other genes, resulting in abnormal activation. This variant occurs in some patients with non-small cell lung cancer and is associated with tumor development and progression. Entrectinib inhibits this abnormal signaling pathway by targeting the activity of ROS1 protein, thereby effectively inhibiting the growth and spread of tumors.

In general, entrectinib is a targeted therapy drug that targets specific cancer gene mutations. By specifically interfering with the activity of abnormal signaling pathways, it inhibits the growth and spread of tumor types such as NTRK gene fusion mutations and ROS1-positive non-small cell lung cancer. The emergence of this drug has brought new treatment options to some cancer patients and has demonstrated significant efficacy in clinical practice. However, as with all medications, patients should consult their physician before receiving entrectinib to learn about its indications, side effects, and interactions with other medications to ensure safe and effective use of the medication.